-  INCLUSION CRITERIA:

          -  Subjects with cytologically or histologically confirmed locally advanced or metastatic
             HPV associated malignancies:

               -  Cervical cancers;

               -  P16+ Oropharyngeal cancers;

               -  Anal cancers;

               -  Vulvar, vaginal, penile, and squamous cell rectal cancers;

               -  Other locally advanced or metastatic solid tumors (e.g., lung, esophagus) that
                  are known HPV+.

          -  Subjects must have measurable disease, per RECIST 1.1.

          -  Subjects must have received prior first line systemic therapy unless the participant
             is not eligible to receive standard therapy or declines standard treatment.

          -  Age >= 18 years.

          -  ECOG performance status <= 2.

          -  Adequate hematologic function at screening, as follows:

               -  Absolute neutrophil count (ANC) >=1 x 10^9/L;

               -  Hemoglobin >= 9 g/dL;

               -  Platelets >=75,000/microliter.

          -  Adequate renal and hepatic function at screening, as follows:

               -  Serum creatinine <= 1.5 x upper limit of normal (ULN) OR Measured or calculated
                  creatinine clearance >=40 mL/min for participant with creatinine levels > 1.5 X
                  institutional ULN (GFR can also be used in place of creatinine or CrCl);

               -  Bilirubin <= 1.5 x ULN OR in subjects with Gilbert's syndrome, a total bilirubin
                  <= 3.0 x ULN;

               -  Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) <= 2.5 x ULN,
                  unless liver metastases are present, then values must be <= 3 x ULN).

          -  The effects of the immunotherapies on the developing human fetus are unknown. For this
             reason and because immunotherapeutic agents as well as other therapeutic agents used
             in this trial are known to be teratogenic, women of child-bearing potential and men
             must agree to use highly effective contraception (hormonal or barrier method of birth
             control; abstinence) prior to study entry and for two months after study treatment.
             Should a woman become pregnant or suspect she is pregnant while she or her partner is
             participating in this study, she should inform her treating physician immediately.

          -  Participants serologically positive for HIV, Hep B, Hep C are eligible as long as the
             viral loads are undetectable by quantitative PCR. HIV positive participants must have
             CD4 count >= 200 cells per cubic millimeter at enrollment, be on stable antiretroviral
             therapy for at least 4 weeks and have no reported opportunistic infections or
             castleman s disease within 12 months prior to enrollment.

          -  Ability of subject to understand and the willingness to sign a written informed
             consent document.

        EXCLUSION CRITERIA:

          -  Participants with prior investigational drug, chemotherapy, immunotherapy or any prior
             radiotherapy (except for palliative bone directed therapy) within the past 28 days
             prior to the first drug administration except if the investigator has assessed that
             all residual treatment-related toxicities have resolved or are minimal and feel the
             participant is otherwise suitable for enrollment. Partaicipants may continue adjuvant
             hormonal therapy in the setting of a definitively treated cancer (e.g. breast cancer).

          -  Known intolerance to or life threatening side effects resulting from prior checkpoint
             inhibitor therapy.

          -  Major surgery within 28 days prior to the first drug administration (minimally
             invasive procedures such as diagnostic biopsies are permitted).

          -  Known active brain or central nervous system metastasis (less than a month out from
             definitive radiotherapy or surgery), seizures requiring anticonvulsant treatment (<3
             months) or clinically significant cerebrovascular accident (<3 months). In order to be
             eligible participant must have repeat CNS imaging at least a month after definitive
             treatment showing stable CNS disease. Participants with evidence of intratumoral or
             peritumoral hemorrhage on baseline imaging are also excluded unless the hemorrhage is
             grade <= 1 and has been shown to be stable on two consecutive imaging scans.

          -  Pregnant women are excluded from this study because these drugs have not been tested
             in pregnant women and there is potential for teratogenic or abortifacient effects.
             Because there is an unknown but potential risk for adverse events in nursing infants
             secondary to treatment of the mother with these immunotherapies, breastfeeding should
             be discontinued if the mother is treated on this protocol.

          -  Active autoimmune disease that might deteriorate when receiving an immunostimulatory
             agent with exception of:

               -  Diabetes type I, eczema, vitiligo, alopecia, psoriasis, hypo- or hyperthyroid
                  disease or other mild autoimmune disorders not requiring immunosuppressive
                  treatment;

               -  Subjects requiring hormone replacement with corticosteroids are eligible if the
                  steroids are administered only for the purpose of hormonal replacement and at
                  doses <= 10 mg of prednisone or equivalent per day;

               -  Administration of steroids for other conditions through a route known to result
                  in a minimal systemic exposure (topical, intranasal, intro-ocular, or inhalation)
                  is acceptable;

               -  Subjects on systemic intravenous or oral corticosteroid therapy with the
                  exception of physiologic doses of corticosteroids (<= the equivalent of
                  prednisone 10 mg/day) or other immunosuppressives such as azathioprine or
                  cyclosporin A are excluded on the basis of potential immune suppression. For
                  these subjects these excluded treatments must be discontinued at least 1 weeks
                  prior to enrollment for recent short course use (<= 14 days) or discontinued at
                  least 4 weeks prior to enrollment for long term use (> 14 days). In addition, the
                  use of corticosteroids as premedication for contrast- enhanced studies is allowed
                  prior to enrollment and on study.

          -  Subjects with a history of serious intercurrent chronic or acute illness, such as
             cardiac or pulmonary disease, hepatic disease, bleeding diathesis or recent (within 3
             months) clinically significant bleeding events, or other illness considered by the
             Investigator as high risk for investigational drug treatment.

          -  Subjects unwilling to accept blood products as medically indicated.

          -  History of non-HPV associated second malignancy within 3 years of enrollment except
             localized malignancy which has been adequately treated or malignancy which does not
             require active systemic treatment (e.g,, low risk CCL). Patients taking adjuvant
             hormonal therapy for definitively treated cancers (e.g. breast cancer) are eligible.

          -  Subjects with a known severe hypersensitivity reaction to a monoclonal antibodies
             (grade >/= 3 NCI-CTCAE v5) will be evaluated by the allergy/immunology team prior to
             enrollment.

          -  Receipt of prior lymphodepleting chemotherapy (e.g. cyclophosphamide, fludarabine) or
             any organ transplantation requiring ongoing immunosuppression.